Spots Global Cancer Trial Database for Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine

Official Title: Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine

Study ID: NCT04672473

Conditions

Malignant Tumor

Interventions

DC-CTL

Study Description

Brief Summary: Tumor-specific antigens can be induced by demethylation drugs. Antigen-targeting DC-CTL cells supposed to eliminate cancer cells efficiently and specifically. In this study investigators co-culture DCs cells with peptides derived from tumor specific antigen to generate antigen-specific DC-CTLs (Ag-CTL). Following treatment with demethylation drugs, Ag-CTL will be used to eliminate tumor cells. This study aims to evaluate the effectiveness and safety of Ag-CTL combined with demethylation drugs.

Detailed Description: A large number of studies have confirmed that demethylated drug decitabine can effectively induce tumor-specific antigen expression. Tumor-specific antigens have strong specificity and are ideal therapeutic targets. In this study, tumor-specific antigens were used as therapeutic targets. The researchers screened the tumor-specific epitope peptides through bioinformatics database combined with in vitro experiments. The peptide-loaded DCs are co-cultured with T lymphocytes to induce the proliferation of CTLs, which are then refusion to tumor patients to treating diseases.